Evidence map›Paper›PMID 39640945›Full record

ArticleSmall science2024

Enhanced efficacy of a TLR3 agonist delivered by cowpea chlorotic mottle virus nanoparticles.

Eunkyeong Jung, Anahid Foroughishafiei, Young Hun Chung, Nicole F Steinmetz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Small science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Plant-Derived Anti-Cancer Therapeutics and Biopharmaceuticals.Bioengineering (Basel, Switzerland) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Eunkyeong JungDepartment of NanoEngineering, University of California San Diego, 9500 Gilman Dr., La Jolla, California 92093, United States.
Anahid ForoughishafieiDepartment of NanoEngineering, University of California San Diego, 9500 Gilman Dr., La Jolla, California 92093, United States.
Young Hun ChungDepartment of Bioengineering, University of California San Diego, 9500 Gilman Dr., La Jolla, California 92093, United States.
Nicole F SteinmetzDepartment of NanoEngineering, University of California San Diego, 9500 Gilman Dr., La Jolla, California 92093, United States.

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9M
Resource for Biocomputing Visualization and InformaticsP41GM103311 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERRIN, THOMAS E · 2012 to 2017
$8.2M
Dual-pronged nano-drug delivery using plant virus-like particles.R01CA224605 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Nicole Franziska Steinmetz · 2017 to 2026
$4.0M
Bioprinting Plant Virus Nanoparticles for Immunotherapy and Relapse Prevention of Ovarian CancerR01CA253615 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHEN, SHAOCHEN, FIERING, STEVEN · 2020 to 2024
$3.1M
Toward translation of a plant virus-based in situ vaccination nanotechnologyR01CA274640 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIERING, STEVEN, RANJAN, ASHISH · 2022 to 2025
$2.5M
JEOL JEM-1400Plus Transmission Electron MicroscopeS10OD023527 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FARQUHAR, MARILYN GIST · 2017 to 2017
$579k
NCI NIH HHS P30 CA023100NCI NIH HHS R01 CA224605NCI NIH HHS R01 CA253615NCI NIH HHS R01 CA274640NIGMS NIH HHS P41 GM103311NIH HHS S10 OD023527
6 · The paper itself

Abstract

Intratumoral immunotherapies are those that are administered directly into a tumor to remodel the local tumor microenvironment and stimulate systemic anti-tumor immunity. Small molecule Toll-like receptor (TLR) agonists are undergoing development as intratumoral immunotherapies, and here we considered the TLR3 agonist poly(I:C). Because small molecule therapeutics often suffer rapid washout effects and ineffective immune cell uptake, we encapsulated poly(I:C) into nanoparticles derived from cowpea chlorotic mottle virus (CCMV). The particles (but not the separate components) stimulated the activity of macrophages

Indexed as

cancer immunotherapycowpea chlorotic mottle virusdrug deliveryintratumoral immunotherapyTLR3 agonistvirus like particles

Identifiers

PMID39640945
PMCPMC11615967

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.